Development of novel agents and combinations for renal carcinoma

Abstract

Based on a better understanding of the pathogenesis of renal carcinoma, the last 5 years has witnessed a rapid transition of novel agents from the bench to the bedside. Multiple new drugs have already been approved for standard use including sunitinib, sorafenib, and temsirolimus with additional agents including everolimus, bevacizumab, and pazopanib under review by the regulatory agencies. This review will highlight the clinical data, which support the use of these novel agents and highlight current approaches exploring combination therapy.